Stocks and InvestingStocks and Investing
Thu, February 17, 2022
Wed, February 16, 2022
Tue, February 15, 2022
Mon, February 14, 2022

Leland Gershell Upgraded (ASND) to Buy and Held Target at $170 on, Feb 14th, 2022


Published on 2024-10-27 19:40:33 - WOPRAI, Leland Gershell
  Print publication without navigation


Leland Gershell of Oppenheimer, Upgraded "Ascendis Pharma A/S" (ASND) to Buy and Held Target at $170 on, Feb 14th, 2022.

Leland has made no other calls on ASND in the last 4 months.



There are 5 other peers that have a rating on ASND. Out of the 5 peers that are also analyzing ASND, 2 agree with Leland's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Yaron Werber of "Cowen & Co." Initiated at Hold and Held Target at $136 on, Thursday, January 6th, 2022
  • Tazeen Ahmad of "B of A Securities" Downgraded from Strong Buy to Hold and Increased Target to $169 on, Wednesday, October 20th, 2021


These are the ratings of the 3 analyists that currently disagree with Leland


  • Derek Archila of "Wells Fargo" Initiated at Buy and Held Target at $176 on, Wednesday, December 8th, 2021
  • Joseph Schwartz of "SVB Leerink" Maintained at Buy with Increased Target to $190 on, Monday, November 15th, 2021
  • Tiago Fauth of "Credit Suisse" Maintained at Buy with Decreased Target to $179 on, Thursday, November 11th, 2021